- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03406611
Pegtibatinase som en enzymterapi til patienter med homocystinuri forårsaget af cystathionin beta-syntase-mangel (COMPOSE)
Et dobbeltblindt, randomiseret, placebokontrolleret, fase 1/2-studie til vurdering af sikkerhed, tolerabilitet, farmakokinetik, farmakodynamik og virkninger på kliniske resultater af Pegtibatinase (TVT-058), administreret subkutant hos patienter med cystathionin beta-syntase-deficient Homocystinuria (KOMPOSER)
Homocystinuri forårsaget af Cystathionine Beta-Synthase (CBS) mangel er en sjælden autosomal-recessiv metabolisk tilstand karakteriseret ved et overskud af homocystein (Hcy) i plasma, væv og urin. Det skyldes reduceret eller fraværende aktivitet af CBS-enzymet og er også kendt som klassisk homocystinuri. Symptomerne forbundet med homocystinuri varierer i sværhedsgrad og tidspunkt for debut på tværs af patienter. Nogle berørte personer kan have milde tegn på lidelsen; andre kan have multisystemisk involvering, herunder potentielt livstruende komplikationer. Homocystinuri kan påvirke mange forskellige organsystemer i kroppen; de fire mest involverede er øjnene, centralnervesystemet, skelettet og det vaskulære system.
De nuværende tilgange til behandling af homocystinuripatienter omfatter en meget restriktiv diæt og brug af kosttilskud. Livstidsoverholdelse af denne diæt er dårlig. Pegtibatinase (TVT-058) repræsenterer en ny terapeutisk tilgang, der inkorporerer brugen af en modificeret version af det native, humane CBS (hCBS) enzym. Målet med behandlingen er at introducere CBS-enzymet i cirkulationen, hvilket resulterer i reducerede Hcy-niveauer, øget cystathionin (Cth) og cystein (Cys) niveauer.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Primary Objective - Cohorts 1-6
Researchers are performing this study to learn if pegtibatinase is safe and tolerable (how it makes participants feel).
Researchers will use medical examination, blood tests, and urine tests to measure side effects (unwanted health problems that may or may not be related to the study treatment), changes in laboratory tests and in the electrical activity of the heart (as measured by electrocardiogram or "ECG"), and if the body makes antibodies to fight against pegtibatinase. Antibodies are proteins that the body makes that may stop pegtibatinase from working or may cause side effects.
Secondary Objectives - Cohorts 1-6
Researchers also want to learn about:
- What are the levels of pegtibatinase in the body after single and repeated doses?
- How does pegtibatinase affect levels of certain substances that are produced when the body breaks down and creates homocysteine?
- What are the effects of pegtibatinase on the eyes, bones, mental health, and cognitive function? Researchers will use blood tests, physical examinations, and questionnaires to answer these questions.
Cohort 7 Objectives
Group 7 is open to children aged 5 to 11 years old (or "pediatric participants") who meet the requirements for the study.
Researchers are performing this part of the study with Group 7 to learn if pegtibatinase is safe and tolerable (how it makes participants feel) and if it increases antibody levels when it is given to children with HCU.
Researchers will use blood tests and physical examinations to measure side effects that happen during the study, changes in laboratory tests, electrical activity of the heart, antibody levels, vital signs, and the number of pediatric participants that have too high or too low levels of methionine. Researchers will use questionnaires to measure the number of pediatric participants that need more protein in their diet.
Researchers are performing this part of the study with Group 7 because they also want to learn about:
- What are the levels of pegtibatinase in the pediatric participant's body after single and repeated doses?
- How does pegtibatinase affect levels of total homocysteine and methionine in the pediatric participant's body? Researchers will use blood tests to answer these questions.
Study Population and Treatments
This study will include children and adults from 5 to 65 years old with HCU. Participants in Groups 1 to 6 were aged 12 to 65 years old, and Group 7 participants will be aged 5 to 11 years old. Participants in the study will take their standard of care treatment.
Groups 1 to 6 have completed this study already. For these groups, 24 participants aged 12 to 65 years old who met the requirements of the study were split into 1 of the 6 groups. For each group, 3 participants were chosen to take pegtibatinase for every 1 participant chosen to take an injection that does not have any medicine in it (or "placebo"). Participants were assigned to pegtibatinase or placebo by chance, like the flip of a coin. This is called "randomization". Neither the researchers nor the participants knew which treatment they were getting until the study was completed. This is known as a "double-blind" approach.
Group 7 is open and will be conducted globally. It will include 10 to 15 pediatric participants aged 5 to 11 years old who meet the requirements of the study. All participants in this group will receive pegtibatinase. All participants will know that this is the treatment that they receive. This is called an "open label" approach. The treatment period will be separated into 3 parts: Part A, Part B, and Part C. Each part will test a different dose of pegtibatinase. After each part, pediatric participants who meet specific requirements will move to the next part. If the pediatric participants do not meet specific requirements to move to the next part, they will have the option to join the ENSEMBLE study (NCT06431893) and continue taking that same dose.
Pegtibatinase or placebo will be given as an injection under the skin (or "subcutaneous injection"). Doses for each group are shown below.
- Group 1: 0.33 mg/kg pegtibatinase or placebo 1 time a week.
- Group 2: 0.66 mg/kg pegtibatinase or placebo 1 time a week.
- Group 3: 1.0 mg/kg pegtibatinase or placebo 1 time a week.
- Group 4: 1.0 mg/kg pegtibatinase or placebo 2 times a week.
- Group 5: 1.5 mg/kg pegtibatinase or placebo 2 times a week.
- Group 6: 2.5 mg/kg pegtibatinase or placebo 2 times a week.
- Group 7:
- Part A: 1.0 mg/kg pegtibatinase 2 times a week for 8 weeks;
- Part B: 1.5 mg/kg pegtibatinase 2 times a week for 8 weeks;
- Part C: 2.5 mg/kg pegtibatinase 2 times a week for 4 weeks.
Study Duration and Visits
Participants in Groups 1 to 6 were in the study for up to 158 weeks, including the screening period of up to 8 weeks, a double-blind treatment period of up to 12 weeks, and an extension period of up to 138 weeks. A continuation study called ENSEMBLE was available to participants. Participants were offered to join the ENSEMBLE study before they finished the extension period of the COMPOSE study.
Pediatric participants in Group 7 may be in the study for up to 42 weeks, including the screening period of up to 10 weeks, open-label treatment period of up to 20 weeks, and up to 12 weeks of additional treatment at the same dose if the ENSEMBLE study is not yet open.
If participants in Group 7 meet all the requirements of the study, they will have up to 53 visits to a study center or at home. If the ENSEMBLE study is not yet open at their site, they can have up to 23 more visits to continue treatment.
These visits can include:
- Blood and urine tests
- Physical examinations
- Questionnaires
- Injections
- Questions about how they are feeling or any problems they are having
Safety / Adverse Events
Researchers will keep track of any medical problems that a participant has during a study (or "adverse event"). All participants in this study will have regular laboratory tests, health checkups, and site visits to watch for health risks and measure safety.
Benefit-Risk Conclusion Researchers have worked to reduce risks to participants in this study. They believe the risks of taking pegtibatinase in this study are justified by the potential benefits that they think pegtibatinase may have for people with HCU.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Travere Call Center
- Telefonnummer: 1-877-659-5518
- E-mail: medinfo@travere.com
Studiesteder
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Afsluttet
- Travere Investigational Site
-
-
Florida
-
Miami, Florida, Forenede Stater, 33136
- Afsluttet
- Travere Investigational Site
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Ikke rekrutterer endnu
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Afsluttet
- Travere Investigational Site
-
-
Maine
-
Portland, Maine, Forenede Stater, 04102
- Afsluttet
- Travere Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Afsluttet
- Travere Investigational Site
-
-
New York
-
New York, New York, Forenede Stater, 10029
- Ikke rekrutterer endnu
- The Mount Sinai Hospital
-
New York, New York, Forenede Stater, 10029
- Afsluttet
- Travere Investigational Site
-
-
North Carolina
-
Morrisville, North Carolina, Forenede Stater, 27560
- Rekruttering
- Science 37 - Virtual Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Afsluttet
- Travere Investigational Site
-
-
-
-
-
Paris, Frankrig, 75015
- Ikke rekrutterer endnu
- Hospital Necker-Enfants Malades, Neurologie Pediatrique
-
-
-
-
-
Doha, Qatar
- Ikke rekrutterer endnu
- Sidra Medicine
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Beskrivelse
Inklusionskriterier:
- Bekræftet diagnose af homocystinuri baseret på genetisk bekræftelse og plasma tHcy ≥50 mikromol og dokumentation for tidligere tHcy niveau ≥80 mikromol
- Villig og i stand til at give skriftligt, underskrevet informeret samtykke og overholde alle undersøgelsesrelaterede procedurer.
- Forsøgspersoner født biologisk som kvinder, der er i den fødedygtige alder, skal have en negativ graviditetstest ved screeningen og være villige til at få foretaget yderligere graviditetstest under undersøgelsen. Forsøgspersoner født biologisk som mænd, der identificerer sig som kvindelige og ikke er i den fødedygtige alder, skal ikke gennemgå graviditetstests
- Seksuelt aktive forsøgspersoner, der er i den fødedygtige alder, eller dem, der har partnere i den fødedygtige alder, skal være villige til at bruge acceptable præventionsmetoder, mens de er i undersøgelsen og i 4 uger efter undersøgelsens afslutning.
- Villig til at opretholde en stabil kost uden væsentlige ændringer, mens du studerer og udfylde en daglig kostdagbog.
Ekskluderingskriterier:
- Tidligere eksponering for pegtibatinase og/eller tidligere deltagelse i et klinisk forsøg, der omfattede administration af pegtibatinase
- Brug af ethvert forsøgsprodukt eller medicinsk udstyr til undersøgelse inden for 30 dage før screening eller under undersøgelse
- Brug eller planlagt brug af injicerbare lægemidler, der indeholder PEG (bortset fra pegtibatinase eller COVID-19-vacciner), inklusive medroxyprogesteron (f.eks. Depo-Provera) injektion, inden for 3 måneder før screening og under undersøgelsesdeltagelse
- Kendt overfølsomhed over for PEG-holdigt produkt eller andre komponenter af pegtibatinase
- En positiv test for HIV-antistof, hepatitis B-overfladeantigen eller hepatitis C-antistof
- En historie med organtransplantation, kronisk immunsuppressiv terapi eller stofmisbrug
- Gravid eller ammer ved screening eller planlægger at blive gravid (selv eller partner) eller at amme på et hvilket som helst tidspunkt under undersøgelsen
- Samtidig sygdom eller tilstand eller planlagt større operation, der ville forstyrre undersøgelsesdeltagelsen eller sikkerheden efter investigators mening.
- Enhver tilstand, der efter investigatorens opfattelse placerer forsøgspersonen i høj risiko for dårlig behandlingsefterlevelse eller for ikke at fuldføre undersøgelsen
- Større operation planlagt i studieperioden
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Pegtibatinase (Cohort 1-6)
Double-Blind Treatment Cohorts (≥12 to ≤65 years)
|
Pegtibatinase steril opløsning til subkutan injektion
Andre navne:
|
|
Placebo komparator: Placebo (Cohort 1-6)
Double-Blind Treatment Cohorts (≥12 to ≤65 years)
|
Normalt saltvand til subkutan injektion
|
|
Eksperimentel: Pegtibatinase (Cohort 7)
Pediatric Open-label Treatment Cohort (≥5 to <12 years)
|
Pegtibatinase steril opløsning til subkutan injektion
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of AEs
Tidsramme: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Incidence of AEs (by type, severity and relationship to study drug)
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Anti-pegtibatinase antibodies
Tidsramme: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Presence and levels of anti-pegtibatinase antibodies in plasma as measured by antibody titers
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Anti-PEG antibodies
Tidsramme: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Presence and levels of anti-PEG antibodies in plasma as measured by antibody titers
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Incidence of hypermethioninemia (Cohort 7 only)
Tidsramme: First dose through End of Treatment (up to Week 32)
|
The number and percentage of participants who develop hypermethioninemia during treatment, based on plasma methionine concentrations exceeding the protocol-defined threshold.
Participants meeting the protocol-defined threshold may undergo dietary management or study treatment modifications, as appropriate.
|
First dose through End of Treatment (up to Week 32)
|
|
Incidence of hypomethioninemia (Cohort 7 only)
Tidsramme: First dose through End of Treatment (up to Week 32)
|
The number and percentage of participants who develop hypomethioninemia during treatment, based on plasma methionine concentrations below the protocol-defined threshold.
Participants meeting the protocol-defined threshold may receive dietary protein supplementation or study treatment modifications, as appropriate.
|
First dose through End of Treatment (up to Week 32)
|
|
The proportion of participants requiring dietary protein rescue (Cohort 7 only)
Tidsramme: First dose through End of Treatment (up to Week 32)
|
The proportion of participants who require initiation of dietary protein supplementation during study treatment to manage protocol-defined low plasma methionine concentrations.
|
First dose through End of Treatment (up to Week 32)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Changes in pegtibatinase levels
Tidsramme: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Changes in pegtibatinase levels following single and repeat administration at specified timepoints
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Changes in Met cycle metabolites levels - tHcy
Tidsramme: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Changes in total homocysteine levels in micromoles
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Changes in Met cycle metabolites levels - total Cys (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
|
Changes in total cysteine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Changes in Met cycle metabolites levels - Me (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
|
Changes in methionine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Changes in Met cycle metabolites levels - Cth (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
|
Changes in cystathionine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Changes in Met cycle metabolites levels - Phe (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
|
Changes in phenylalanine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Descriptive ophthalmology examination findings (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
|
Comprehensive ophthalmological examination (for each eye: visual acuity [myopia, hyperopia, exotropia], slit lamp examination [ectopic lentis, cataracts, corneal abrasion, and uveitis], retinal examination [retinal degeneration, retinal detachment, retinitis pigmentosa, uveitis)]).
Assessment of presence and severity of findings.
|
Through double-blind study completion, approximately 10 months per patient
|
|
Bone densitometry using dual-energy X-ray absorptionmetry (DEXA) scans (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
|
|
Cognitive assessments using the National Institutes of Health Toolbox Cognition Battery score (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
|
|
Patient Reported Outcome (PRO): Quality of Life in Neurological Disorders [Neuro-QoL] (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
|
The Quality of Life in Neurological Disorders [Neuro-QoL] includes Anxiety Short Form, Depression Short Form, Satisfaction with Social Roles Short Form, Cognition Function Short Form for 18+ years of age; Anxiety Short Form, Depression Short Form, Social Relations - Interaction with Peers Short Form, and Cognitive Function Short Form for Ages 12 to 17 years old
|
Through double-blind study completion, approximately 10 months per patient
|
|
Patient Reported Outcome (PRO): Quality of Life by 36-Item Short Form Survey [SF-36] (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
|
|
Patient Reported Outcome (PRO): Quality of Life by EuroQol 5-Dimentional Instrument [EQ 5D] (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Michael Imperiale, MD, Travere Therapeutics, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Metabolisme, medfødte fejl
- Genetiske sygdomme, medfødte
- Metaboliske sygdomme
- Bindevævssygdomme
- Hjernesygdomme, metaboliske, medfødte
- Hjernesygdomme, metaboliske
- Aminosyremetabolisme, medfødte fejl
- Hyperhomocysteinæmi
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Ernæringsmæssige og metaboliske sygdomme
- Hud- og bindevævssygdomme
- Homocystinuri
Andre undersøgelses-id-numre
- CBS-HCY-CT-01
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
IPD-delingsadgangskriterier
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .